ClinicalTrials.gg
RecruitingNCT06207279Updated Feb 28, 2024

Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale

An observational study in Depression, Insomnia and Attention Disturbances, sponsored by Peking University Sixth Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Peking University Sixth Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
240
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 358 studies in Depression with a site in China — 119 open to participants now, 138 under way, 3 of them phase 3. Depression · China.

Planned enrollment
44th of 74
240 · median 306
Started
2023
with 43 others
Observational
74 of 358
30 open now
Primary completion
2024-12
later than 19 of 137 live
Registered
192nd of 358
by date

Among the 358 studies in Depression with a site in China, this one is the 44th largest by planned enrollment of the 74 observational ones that give a count, is one of 44 that started in 2023, is one of 74 observational ones, reaches primary completion later than 19 of the 137 other live ones, and was the 192nd registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

119 of the 358 studies in Depression with a site in China are open now. Recruiting first, the newest first:

114 more — sign in →

All 119 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 358 studies in Depression with a site in China, or all of them as a file.
02

Study summary

This study, based on preliminary experimental results, literature review, and expert consultations, developed the Attentional Rating Scale (ARS). The aim was to rapidly assess participants' attention and potential influencing factors. The research focused on the scale's reliability and validity among healthy adults. Additionally, the Attention Network Test (ANT) served as the gold standard for evaluating attention. The study attempted to identify correlations between various dimensions of attention and the three attentional networks.

Read the detailed description
  1. To adiministrate 60 healthy subjects to evaluate internal consistency reliability.
  2. To choose 20 cases for ARS retesting 7 days after the first ARS evaluation.
  3. To evaluate the split half reliability through the Spearman Brown coefficient.
  4. To apply principal component analysis for structural validity analysis.
  5. Using the Attention Network Test (ANT) and Toronto Hospital Alertness Test (THE) as gold standards, the Pearson correlation coefficient was used for criterion validity analysis.
  6. To administrate 60 patients with MDD, ADHD and insomnia disorder testing the discrimination validity of ARS.
03

Conditions studied

  • Depression
  • Insomnia
  • Attention Disturbances
  • Healthy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Sixty cases of patients diagnosed with Major Depressive Disorder (MDD), ADHD and insomnia disorder separately are recruited from outpatient clinics and hospital wards. Additionally, sixty healthy individuals are recruited from the community as control subjects.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Major Depressive Disorder (MDD) or attention deficit hyperactivity disorder (ADHD) diagnosed according to , or Chronic Insomnia Disorder diagnosed according to ICSD-3
  2. Ages between 18 and 60 years old
  3. Right-handed
  4. Educational level ≥5 years or IQ ≥90, capable of understanding and reading Chinese.

Exclusion criteria

Exclusion Criteria:

  1. Currently diagnosed with any other mental disorders (according to MINI 7.0) or ICSD-3 sleep-wake disorders, apart from MDD, ADHD or insomnia disorder
  2. Currently and past history of neurological disorders and physical illnesses with subjectives
  3. Consumed alcohol in the week preceding the enrollment
  4. Using antidepressants, antipsychotics, mood stabilizers, or other central nervous system-acting drugs for at least 4 weeks in the current episode
  5. Undergoing any physical treatments such as ECT, neuromodulation therapy or Traditional Chinese Medicine treatment in the past 6 months
  6. Refused to sign the form
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Major Depressive Disorder

    Patients meeting the diagnostic criteria for Major Depressive Disorder (MDD) according to DSM-5.

    Diagnostic Test: rating

  • Chronic Insomnia Disorder

    Patients meeting the diagnostic criteria for Chronic Insomnia Disorder according to ICSD-3.

    Diagnostic Test: rating

  • Health Control

    Healthy population.

    Diagnostic Test: rating

  • Attention Deficit and hyperactivity Disorder

    Patients meeting the diagnostic criteria for Attention Deficit and hyperactivity Disorder (ADHD) according to DSM-5.

    Diagnostic Test: rating

Interventions

  • Diagnostic testrating

    rating scales, test ANT

06

What researchers measure

Primary outcomes

  1. Developing Attention Rating Scale(ARS)

    The Attention Assessment Scale is developing as a tool to assess attention ability designed for self-rating scale. Its purpose is to swiftly evaluate the attention levels of adults. There are 30 items in ARS. The minimum value is 1 and maximum value is 5, and the higher scores mean a better outcome for attention ability.

    Time frame: 3 months

  2. Reliability and Validity of the Attention Assessment Scale.

    Reliability 1. Cronbach α of ARS should be above 0.8 that means good reliability. 2. The intra group correlation value for retesting reliability should be above 0.8 that means good retesting reliability. Validity 1. The split half reliability measured and factor analysis to test constuctive validity of ARS. 2. The correlation coefficient r with ANT and the correlation coefficient r with THAT should be statistic significant, that means good validity of attention ability for Attention Assessment Scale.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2024, 15 months after the start.

Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 15 months is below that.

Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Jan 16, 2024
StartActual
Sep 28, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06207279
Lead sponsor
Peking University Sixth Hospital
Responsible party
Xueqin Wang (Principle Investigator, Peking University Sixth Hospital) — Principal investigator
First posted
Jan 16, 2024
Start date
Sep 28, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Feb 28, 2024

Study contacts

Xinyang Zhang, master
Contact
zhangxinyang2022@bjmu.edu.cn
+8610-62723770
Xueqin Wang, doctor
principal investigator · Peking University Sixth Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion